Corrective Phases R...
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$1.46 0.02 | 1.39%
06/04/12 - 11:55 AM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -30.88M | -46.68M | -22.06M | -6.86M |
| Operating Gains/Losses | 0.00 | 6.73K | 3.44K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 3.21M | 1.35M | 1.14M | 578.00K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 26.00K | 300.00K | 0.00 | 0.00 |
| Other Non-Cash Items | -11.31M | 21.46M | 10.88M | -437.00K |
| Net Cash From Continuing Operations | -37.37M | -24.08M | -10.46M | -6.72M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -37.37M | -24.08M | -10.46M | -6.72M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 200.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 1.49M | 1.74M | 4.05M | 9.88M |
| Purchases of Property, Plant & Equipment | -2.61M | -1.64M | -515.44K | -8.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -4.98M | -3.24M | 0.00 | -247.00K |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -6.10M | -3.13M | 3.53M | 9.62M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 23.62M | 37.35M | 35.48M | 0.00 |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 23.62M | 37.35M | 35.48M | 0.00 |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -19.84M | 10.14M | 28.55M | 2.90M |
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
- UserTA stocks
- ContributorBarron's Activist Stocks 8-...
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- Contributor10 Biotech Stocks on Clinic...
- ContributorBarron's Insider Purchases ...
- User52 Week High Strategy
Latest DCTH Headlines from TheStreet
- BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- Biotech Stock Mailbag: Mela Sciences 09.09.11 | 06:09 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- Biotech Stock Mailbag: Celsion 05.13.11 | 08:05 am
- 'Mad Money Lightning Round': Go for Exelixis 04.26.11 | 07:04 pm
- Biotech Stock Mailbag: Amarin 04.22.11 | 07:04 am
- Sweet Spot in Biotech Investing 04.13.11 | 12:04 pm
- Delcath: Safety Questions Behind FDA Delay 02.23.11 | 07:02 am
- Delcath Hit With FDA Approval Delay 02.22.11 | 10:02 am
- 10 Health Care Stocks With 100% Buy Ratings 01.28.11 | 07:01 am
Press Releases for DCTH
- Delcath Announces First CHEMOSAT Procedures In Germany - PR Newswire 02.27.12 | 06:02 am
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
- Delcath Submits CE Mark Technical File For Hepatic ChemoSAT⢠Delivery System - PR Newswire 12.06.10 | 06:12 am
- Delcath Names Bernard R. Tyrrell As Senior Vice President For North American Sales And Marketing - PR Newswire 12.01.10 | 06:12 am
- Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010 - Business Wire 11.10.10 | 05:11 pm
- Delcath Systems Announces Third Quarter Progress Report Conference Call - PR Newswire 10.27.10 | 06:10 am
Partner Headlines for DCTH
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer - NASDAQ 05.25.12 | 04:05 pm
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
- 4 Stocks Attracting Heavy Trading Interest - Wall St. Cheat Sheet 05.25.12 | 12:05 pm
- Ultimate Market Recap: Talbots Tanks, Facebook Fiasco Continues - Wall St. Cheat Sheet 05.25.12 | 06:05 am
- Company News for January 03, 2012 - Corporate Summary - Zacks 01.03.12 | 10:01 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Delcath Announces Updated Efficacy Results from Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver - Benzinga 09.23.11 | 06:09 pm
- Friday's Top Performing Small Cap Stocks (MDS, MNKD, FXCM, FOE, DCTH) - NASDAQ 08.15.11 | 01:08 pm
